Systems pharmacology of adverse event mitigation by drug combinations

Science Translational Medicine

Volumn 5, Issue 206, 2013, Pages

  Zhao, Shan ^a   Nishimura, Tomohiro ^a,b   Chen, Yibang ^a   Azeloglu, Evren U ^a   Gottesman, Omri ^a   Giannarelli, Chiara ^a   Zafar, Mohammad U ^a   Benard, Ludovic ^a   Badimon, Juan J ^a   Hajjar, Roger J ^a   Goldfarb, Joseph ^a   Iyengar, Ravi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; EXENDIN 4; FENTANYL; FOLIC ACID; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LISINOPRIL; METFORMIN; MONTELUKAST; NICOTINIC ACID; PARACETAMOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPOFOL; QUETIAPINE; ROSIGLITAZONE; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ADVERSE OUTCOME; ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DATABASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HEART FUNCTION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYPHARMACY; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SUICIDE; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; BLOOD COAGULATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES AS TOPIC; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART FUNCTION TESTS; HUMANS; MICE; MYOCARDIAL INFARCTION; PEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; SYSTEMS BIOLOGY; THIAZOLIDINEDIONES; THROMBELASTOGRAPHY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOMS;

EID: 84885441247     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006548     Document Type: Article

References (27)

1. L. Brunton, B. Chabner, B. Knollman, Goodman and Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill Professional, New York, ed. 12, 2010), p. 1808.
2. J. Scheiber, J. L. Jenkins, S. C. K. Sukuru, A. Bender, D. Mikhailov, M. Milik, K. Azzaoui, S. Whitebread, J. Hamon, L. Urban, M. Glick, J. W. Davies, Mapping adverse drug reactions in chemical space. J. Med. Chem. 52, 3103-3107 (2009).
3. W. E. Evans, M. V. Relling, Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).
4. International Warfarin Pharmacogenetics Consortium, T. E. Klein, R. B. Altman, N. Eriksson, B. F. Gage, S. E. Kimmel, M. T. M. Lee, N. A. Limdi, D. Page, D. M. Roden, M. J. Wagner, M. D. Caldwell, J. A. Johnson, Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
5. A. Ma'ayan, S. L. Jenkins, J. Goldfarb, R. Iyengar, Network analysis of FDA approved drugs and their targets. Mt. Sinai J. Med. 74, 27-32 (2007).
6. S. I. Berger, R. Iyengar, Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
7. G. W. Ostheimer, A comparison of glycopyrrolate and atropine during reversal of nondepolarizing neuromuscular block with neostigmine. Anesth. Analg. 56, 182-186 (1977).
8. S. I. Berger, A. Ma'ayan, R. Iyengar, Systems pharmacology of arrhythmias. Sci. Signal. 3, ra30 (2010).
9. N. P. Tatonetti, J. C. Denny, S. N. Murphy, G. H. Fernald, G. Krishnan, V. Castro, P. Yue, P. S. Tsao, P. S. Tsau, I. Kohane, D. M. Roden, R. B. Altman, Detecting drug interactions from adverse-event reports: Interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133-142 (2011).
10. L. S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E. B. Rappaport, A. Salzman; Rosiglitazone Clinical Trials Study Group, Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24, 308-315 (2001).
11. S. E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
12. S. E. Nissen, K. Wolski, Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
13. G. S. Harmon, D. S. Dumlao, D. T. Ng, K. E. Barrett, E. A. Dennis, H. Dong, C. K. Glass, Pharmacological correction of a defect in PPAR-γ signaling ameliorates disease severity in Cftr-deficient mice. Nat. Med. 16, 313-318 (2010).
14. N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, J. Plutzky, PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546-551 (1999).
15. H. Liu, Y. Hu, R. W. Simpson, A. E. Dear, Glucagon-like peptide-1 attenuates tumour necrosis factor-α-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J. Endocrinol. 196, 57-65 (2008).
16. A. L. Harte, P. G. McTernan, C. L. McTernan, S. A. Smith, A. H. Barnett, S. Kumar, Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes. Metab. 5, 302-310 (2003).
17. R. M. Craft, J. J. Chavez, C. C. Snider, R. A. Muenchen, R. C. Carroll, Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J. Lab. Clin. Med. 145, 309-315 (2005).
18. J. H. Gurwitz, T. S. Field, L. R. Harrold, J. Rothschild, K. Debellis, A. C. Seger, C. Cadoret, L. S. Fish, L. Garber, M. Kelleher, D. W. Bates, Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116 (2003).
19. A. Abadie, Semiparametric difference-in-differences estimators. Rev. Econ. Stud. 72, 1-19 (2005).
20. M. Bertrand, E. Duflo, S. Mullainathan, How much should we trust differences-in-differences estimates? Q. J. Econ. 119, 249-275 (2004).
21. P. S. Denker, P. E. Dimarco, Exenatide (exendin-4)-induced pancreatitis: A case report. Diabetes Care 29, 471 (2006).
22. T. K. Nordt, H. Sawa, S. Fujii, B. E. Sobel, Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91, 764-770 (1995).
23. J. Seok, H. S. Warren, A. G. Cuenca, M. N. Mindrinos, H. V. Baker, W. Xu, D. R. Richards, G. P. McDonald-Smith, H. Gao, L. Hennessy, C. C. Finnerty, C. M. López, S. Honari, E. E. Moore, J. P. Minei, J. Cuschieri, P. E. Bankey, J. L. Johnson, J. Sperry, A. B. Nathens, T. R. Billiar, M. A. West, M. G. Jeschke, M. B. Klein, R. L. Gamelli, N. S. Gibran, B. H. Brownstein, C. Miller-Graziano, S. E. Calvano, P. H. Mason, J. P. Cobb, L. G. Rahme, S. F. Lowry, R. V. Maier, L. L. Moldawer, D. N. Herndon, R. W. Davis, W. Xiao, R. G. Tompkins; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program, Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 110, 3507-3512 (2013).
24. E. Birman-Deych, A. D. Waterman, Y. Yan, D. S. Nilasena, M. J. Radford, B. F. Gage, Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med. Care 43, 480-485 (2005).
25. L. A. Petersen, S. Wright, S. L. Normand, J. Daley, Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J. Gen. Intern. Med. 14, 555-558 (1999).
26. F. Zhao, Z. Xuan, L. Liu, M. Q. Zhang, TRED: A Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Res. 33, D103-D107 (2005).
27. M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin, G. Sherlock, Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).